Wanbury launches next-gen iron supplement ‘C RED' to revolutionize anemia management in India
By Aman Shukla Published on June 27, 2025, 09:44 IST
Wanbury Limited, a well-established name in the pharmaceutical space, has launched its latest innovation — Wanbury C RED — a next-gen Liposomal Iron supplement aimed at tackling anemia more effectively.
This new formula combines Ferric Diphosphate (Ferric Pyrophosphate), Vitamin C, Vitamin B12, and Folic Acid to offer better absorption, fewer gastric side effects, and no metallic aftertaste — common issues with traditional iron supplements. Most importantly, it avoids calcium chelation, making it safe for long-term use, particularly for pregnant women and those with chronic iron deficiency.
Wanbury C RED is already receiving positive feedback from healthcare professionals across North and South India. Encouraged by this early success, the company plans to roll out the supplement nationwide in the coming months.
The launch also marks Wanbury's return to the iron supplement segment after divesting its earlier blockbuster brand C Pink to Cipla. With C RED , Wanbury aims to reclaim leadership in the gynecology and anemia therapy space.
With anemia still affecting over 40% of India's population, Wanbury's timely innovation could play a vital role in improving public health outcomes.
Ahmedabad Plane Crash
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
a day ago
- Business Upturn
Rainbow Children's Medicare acquires majority stake in Prashanthi Hospital
By Aman Shukla Published on June 28, 2025, 14:30 IST Rainbow Children's Medicare Limited (RCML) has announced the acquisition of a majority stake in Prashanthi Medicare Private Limited, a reputed 100-bed NABH-accredited hospital in Warangal, Telangana. The acquisition marks a strategic expansion into tier-II cities and enhances RCML's presence in southern India. Established in 2015 by Dr. Prasanthi Macha, Prashanthi Hospital is recognized for excellence in obstetrics, gynecology, neonatology, pediatrics, and minimally invasive surgery. The hospital has built a strong regional reputation and continues to serve as a trusted destination for maternal and child healthcare in Warangal, Telangana's second-largest district. With this acquisition, RCML's total bed capacity increases to 2,035 across 20 hospitals in seven cities. The transaction, valued at approximately ₹32.60 crore (subject to working capital adjustments), is based on 9x estimated FY25 adjusted EBITDA and will be funded through internal accruals and cash reserves. RCML will acquire a 76% equity stake and 100% of the Non-convertible Redeemable Preference Shares (NCRPS), while Dr. Macha and associates will retain a 24% minority stake. Post-acquisition, the facility will operate under a dual brand: Rainbow Children's Hospital for pediatric services and Prashanthi with BirthRight for women's health services. The integration will support RCML's hub-and-spoke model, ensuring efficient referrals and clinical alignment with its Hyderabad tertiary care hub. Ahmedabad Plane Crash Rainbow Children's Medicare Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
2 days ago
- Business Upturn
Wanbury launches next-gen iron supplement ‘C RED' to revolutionize anemia management in India
By Aman Shukla Published on June 27, 2025, 09:44 IST Wanbury Limited, a well-established name in the pharmaceutical space, has launched its latest innovation — Wanbury C RED — a next-gen Liposomal Iron supplement aimed at tackling anemia more effectively. This new formula combines Ferric Diphosphate (Ferric Pyrophosphate), Vitamin C, Vitamin B12, and Folic Acid to offer better absorption, fewer gastric side effects, and no metallic aftertaste — common issues with traditional iron supplements. Most importantly, it avoids calcium chelation, making it safe for long-term use, particularly for pregnant women and those with chronic iron deficiency. Wanbury C RED is already receiving positive feedback from healthcare professionals across North and South India. Encouraged by this early success, the company plans to roll out the supplement nationwide in the coming months. The launch also marks Wanbury's return to the iron supplement segment after divesting its earlier blockbuster brand C Pink to Cipla. With C RED , Wanbury aims to reclaim leadership in the gynecology and anemia therapy space. With anemia still affecting over 40% of India's population, Wanbury's timely innovation could play a vital role in improving public health outcomes. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
2 days ago
- Business Upturn
Biocon subsidiary gets Health Canada nod for YESAFILI
By Aman Shukla Published on June 27, 2025, 09:19 IST Biocon Biologics Ltd. (BBL), a subsidiary of Biocon Ltd., has received a Notice of Compliance from Health Canada for YESAFILI™ (aflibercept), marking a significant milestone in the company's global biosimilars journey. The regulatory approval, granted on June 26, 2025, makes YESAFILI the first biosimilar to EYLEA® (aflibercept) to be approved in Canada. The product will be available in both vial and prefilled syringe forms (2 mg/0.05 mL), with its commercial launch set for July 4, 2025. YESAFILI is a vascular endothelial growth factor (VEGF) inhibitor designed to treat several serious eye conditions. These include neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and visual impairment due to macular edema caused by retinal vein occlusion (CRVO and BRVO), as well as myopic choroidal neovascularization (myopic CNV). The approval is backed by a robust data package encompassing analytical, nonclinical, and clinical studies. Health Canada concluded that YESAFILI matches EYLEA in quality, safety, and effectiveness, with no clinically meaningful differences. This milestone not only reinforces Biocon Biologics' capabilities in developing high-quality biosimilars but also enhances patient access to affordable treatment options in Canada. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
